<DOC>
	<DOC>NCT02291809</DOC>
	<brief_summary>The primary objective is to compare &amp; evaluate between the treatment groups the changes in decline/reduction of HIV viral load &amp; increase changes in WBC white blood cell counts in the adult Remune dose vs the low dose Remune placebo groups. Additional objectives include changes in CD4+ &amp; CD8+ T cell counts along with increased HIV immunity.</brief_summary>
	<brief_title>REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety &amp; Efficacy Clinical Study</brief_title>
	<detailed_description>This is a 26 subject Multi Center double-blind randomized, Safety &amp; Efficacy, pediatric HIV/AIDS Phase II study, to primarily to evaluate the safety and efficacy of HIV-1 immunogen and secondarily to examine changes in CD4+ &amp; CD8+ T cell counts, determine Remune vaccines effect of multiple inoculations of HIV-1 immunogen on viral replication in children with HIV-1 infection &amp; immunogenicity of Remune. Multi-center, randomized , double-blind, placebo-controlled, two arm parallel design study of Remune.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children clinically diagnosed with HIV that are 3 months of age to the age 16 years old Subjects on any approved FDA antiviral medication except triple cocktail HAART drugs Truvada Triple cocktail HAART drugs Healthy subjects</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV/AIDS</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Vaccine</keyword>
	<keyword>HIV-1 Immunogen</keyword>
</DOC>